LE-SN38

Drug Profile

LE-SN38

Alternative Names: LE SN38; Liposome encapsulated SN38; SN-38 liposomal

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator NeoPharm Inc
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 18 Oct 2016 Discontinued - Phase-II for Colorectal cancer (Second-line therapy or greater) in USA (IV)
  • 19 Jul 2011 No development reported - Phase-II for Colorectal cancer in USA (IV)
  • 13 May 2009 Suspended - Phase-II for Colorectal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top